Cardlytics (NASDAQ:CDLX) Stock Rating Upgraded by Wall Street Zen

Cardlytics (NASDAQ:CDLX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

CDLX has been the topic of several other research reports. Bank of America reaffirmed an “underperform” rating on shares of Cardlytics in a research report on Thursday, March 5th. Evercore set a $1.00 price objective on Cardlytics in a report on Friday, March 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardlytics in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $1.75.

Cardlytics Stock Performance

Shares of NASDAQ:CDLX opened at $1.13 on Friday. The firm has a market cap of $62.23 million, a PE ratio of -0.58 and a beta of 0.91. The company has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $1.34. Cardlytics has a 12-month low of $0.66 and a 12-month high of $3.28.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.08). The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $54.46 million. Cardlytics had a negative net margin of 44.36% and a negative return on equity of 370.98%. As a group, equities research analysts forecast that Cardlytics will post -1.52 EPS for the current fiscal year.

Insider Transactions at Cardlytics

In other news, insider Nicholas Hollmeyer Lynton sold 40,296 shares of Cardlytics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $0.99, for a total value of $39,893.04. Following the completion of the transaction, the insider directly owned 167,856 shares of the company’s stock, valued at approximately $166,177.44. The trade was a 19.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Amit Gupta sold 62,549 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $0.99, for a total transaction of $61,923.51. Following the sale, the chief executive officer directly owned 1,111,445 shares of the company’s stock, valued at approximately $1,100,330.55. This represents a 5.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 254,278 shares of company stock worth $247,053. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Cardlytics

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Cardlytics by 262.7% during the 3rd quarter. Bank of America Corp DE now owns 1,632,786 shares of the company’s stock worth $3,968,000 after purchasing an additional 1,182,593 shares during the period. Quinn Opportunity Partners LLC grew its stake in Cardlytics by 900.0% during the 3rd quarter. Quinn Opportunity Partners LLC now owns 1,100,000 shares of the company’s stock worth $2,673,000 after buying an additional 990,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Cardlytics by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 654,472 shares of the company’s stock worth $753,000 after buying an additional 20,908 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in Cardlytics in the third quarter worth $1,260,000. Finally, UBS Group AG increased its position in Cardlytics by 112.5% in the third quarter. UBS Group AG now owns 458,066 shares of the company’s stock worth $1,113,000 after buying an additional 242,536 shares during the period. 68.10% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.